Amedeo Smart

Free Medical Literature Service

 

Amedeo

Gynecology
  Free Subscription

Articles published in
Lancet
    November 2024
  1. LORUSSO D, Yamada K, Li K, Cerrotta A, et al
    Pembrolizumab for locally advanced cervical cancer - Authors' reply.
    Lancet. 2024;404:2051-2052.
    >> Share

  2. DONG B, Lu Y, Wang Y, Sun P, et al
    Pembrolizumab for locally advanced cervical cancer.
    Lancet. 2024;404:2050.
    >> Share

  3. SCHMID MP, Petric P, Mahantshetty U, Kirisits C, et al
    Pembrolizumab for locally advanced cervical cancer.
    Lancet. 2024;404:2050-2051.
    >> Share

  4. KAMRAVA M, Beriwal S
    Pembrolizumab for locally advanced cervical cancer.
    Lancet. 2024;404:2049.
    >> Share

  5. MURAKAMI N, Okonogi N, Terao Y, Shikama N, et al
    Pembrolizumab for locally advanced cervical cancer.
    Lancet. 2024;404:2049-2050.
    >> Share


  6. Global, regional, and national stillbirths at 20 weeks' gestation or longer in 204 countries and territories, 1990-2021: findings from the Global Burden of Disease Study 2021.
    Lancet. 2024 Nov 4:S0140-6736(24)01925-1. doi: 10.1016/S0140-6736(24)01925.
    >> Share

    October 2024
  7. MCCORMACK M, Eminowicz G, Gallardo D, Diez P, et al
    Induction chemotherapy followed by standard chemoradiotherapy versus standard chemoradiotherapy alone in patients with locally advanced cervical cancer (GCIG INTERLACE): an international, multicentre, randomised phase 3 trial.
    Lancet. 2024;404:1525-1535.
    >> Share

  8. DUSKA LR, Randall LM
    Progress in the treatment paradigms for locally advanced cervical cancer.
    Lancet. 2024;404:1494-1496.
    >> Share

  9. WU X, Sun Y, Yang H, Wang J, et al
    Cadonilimab plus platinum-based chemotherapy with or without bevacizumab as first-line treatment for persistent, recurrent, or metastatic cervical cancer (COMPASSION-16): a randomised, double-blind, placebo-controlled phase 3 trial in China.
    Lancet. 2024 Oct 15:S0140-6736(24)02135-4. doi: 10.1016/S0140-6736(24)02135.
    >> Share

  10. SUN C, Ma D
    Embracing more treatment choices for metastatic, recurrent, or persistent cervical cancer.
    Lancet. 2024 Oct 15:S0140-6736(24)02196-2. doi: 10.1016/S0140-6736(24)02196.
    >> Share

  11. THE LANCET
    Endometriosis: addressing the roots of slow progress.
    Lancet. 2024;404:1279.
    >> Share

    September 2024
  12. SHARP G, Randhawa A, Fernando AN
    Reflections on The Lancet menopause Series.
    Lancet. 2024 Sep 25:S0140-6736(24)01710-0. doi: 10.1016/S0140-6736(24)01710.
    >> Share

  13. BROWN L, Hunter MS, Crandall CJ, Connors HJ, et al
    Reflections on The Lancet menopause Series - Authors' reply.
    Lancet. 2024 Sep 25:S0140-6736(24)01712-4. doi: 10.1016/S0140-6736(24)01712.
    >> Share

  14. STUCKEY BGA
    Reflections on The Lancet menopause Series.
    Lancet. 2024 Sep 25:S0140-6736(24)01709-4. doi: 10.1016/S0140-6736(24)01709.
    >> Share

  15. XIAO Y, Shen M, Chen X
    Reflections on The Lancet menopause Series.
    Lancet. 2024 Sep 25:S0140-6736(24)01711-2. doi: 10.1016/S0140-6736(24)01711.
    >> Share

  16. GENNIGENS C
    Hope emerging in the locally advanced cervical cancer landscape.
    Lancet. 2024 Sep 13:S0140-6736(24)01918-4. doi: 10.1016/S0140-6736(24)01918.
    >> Share

  17. LORUSSO D, Xiang Y, Hasegawa K, Scambia G, et al
    Pembrolizumab or placebo with chemoradiotherapy followed by pembrolizumab or placebo for newly diagnosed, high-risk, locally advanced cervical cancer (ENGOT-cx11/GOG-3047/KEYNOTE-A18): overall survival results from a randomised, double-blind, placebo-
    Lancet. 2024 Sep 13:S0140-6736(24)01808-7. doi: 10.1016/S0140-6736(24)01808.
    >> Share

    August 2024
  18. RYDELIUS J, Hognert H, Kopp-Kallner H, Brandell K, et al
    First dose of misoprostol administration at home or in hospital for medical abortion between 12-22 gestational weeks in Sweden (PRIMA): a multicentre, open-label, randomised controlled trial.
    Lancet. 2024;404:864-873.
    >> Share

  19. MOSESON H, Gerdts C
    Expanding access, reducing burdens, and improving person-centred care in abortion.
    Lancet. 2024;404:826-827.
    >> Share

  20. FIGUERAS F, Rial-Crestelo M, Gratacos E
    Cerebroplacental ratio in low-risk pregnancies: the RATIO37 trial - Authors' reply.
    Lancet. 2024;404:751-752.
    >> Share

  21. GILES-CLARK HJ, Rolnik DL, Hodges RJ, Skinner SM, et al
    Cerebroplacental ratio in low-risk pregnancies: the RATIO37 trial.
    Lancet. 2024;404:750.
    >> Share

  22. BACON I, Hezelgrave NL, Cerdeira AS, Mylrea-Foley B, et al
    Cerebroplacental ratio in low-risk pregnancies: the RATIO37 trial.
    Lancet. 2024;404:750-751.
    >> Share

  23. KAMIHARA Y, Nagase H, Ishikawa H
    Cerebroplacental ratio in low-risk pregnancies: the RATIO37 trial.
    Lancet. 2024;404:749-750.
    >> Share

  24. MEIJERINK L, Terstappen F, Depmann M, Bekker M, et al
    Cerebroplacental ratio in low-risk pregnancies: the RATIO37 trial.
    Lancet. 2024;404:749.
    >> Share

  25. BORNSTEIN E, Vintzileos A
    Cerebroplacental ratio in low-risk pregnancies: the RATIO37 trial.
    Lancet. 2024;404:748-749.
    >> Share

  26. WEI F, Georges D, Man I, Baussano I, et al
    Causal attribution of human papillomavirus genotypes to invasive cervical cancer worldwide: a systematic analysis of the global literature.
    Lancet. 2024;404:435-444.
    >> Share

  27. SCHIFFMAN M, de Sanjose S
    The rational design of cervical cancer prevention strategies.
    Lancet. 2024;404:406-407.
    >> Share

    July 2024
  28. ALVES L
    New abortion bill in Brazil sparks backlash.
    Lancet. 2024;404:17.
    >> Share

    June 2024
  29. HO VNA, Pham TD, Nguyen NT, Wang R, et al
    Livebirth rate after one frozen embryo transfer in ovulatory women starting with natural, modified natural, or artificial endometrial preparation in Viet Nam: an open-label randomised controlled trial.
    Lancet. 2024 Jun 26:S0140-6736(24)00756-6. doi: 10.1016/S0140-6736(24)00756.
    >> Share

  30. JAFFE S
    US Supreme Court protects access to abortion medication.
    Lancet. 2024;403:2679-2680.
    >> Share

  31. SWEETING A, Hannah W, Backman H, Catalano P, et al
    Epidemiology and management of gestational diabetes.
    Lancet. 2024 Jun 18:S0140-6736(24)00825-0. doi: 10.1016/S0140-6736(24)00825.
    >> Share

  32. HIVERT MF, Backman H, Benhalima K, Catalano P, et al
    Pathophysiology from preconception, during pregnancy, and beyond.
    Lancet. 2024 Jun 18:S0140-6736(24)00827-4. doi: 10.1016/S0140-6736(24)00827.
    >> Share

    May 2024
  33. SAMARASINGHE SNS, Leca B, Alabdulkader S, Dimitriadis GK, et al
    Bariatric surgery for spontaneous ovulation in women living with polycystic ovary syndrome: the BAMBINI multicentre, open-label, randomised controlled trial.
    Lancet. 2024 May 20:S0140-6736(24)00538-5. doi: 10.1016/S0140-6736(24)00538.
    >> Share

  34. MORIN-PAPUNEN L
    Bariatric surgery in women with PCOS and obesity.
    Lancet. 2024 May 20:S0140-6736(24)00811-0. doi: 10.1016/S0140-6736(24)00811.
    >> Share

    April 2024
  35. STRAND TA, McCann A, Kvestad I, Chandyo RK, et al
    Vitamin B12 deficiency in pregnant women - Authors' reply.
    Lancet. 2024;403:1450.
    >> Share

  36. SEN S
    Vitamin B12 deficiency in pregnant women.
    Lancet. 2024;403:1449-1450.
    >> Share

    March 2024
  37. JOHANSSON K, Bodnar LM, Stephansson O, Abrams B, et al
    Safety of low weight gain or weight loss in pregnancies with class 1, 2, and 3 obesity: a population-based cohort study.
    Lancet. 2024 Mar 28:S0140-6736(24)00255-1. doi: 10.1016/S0140-6736(24)00255.
    >> Share

  38. GAILLARD R
    Optimising gestational weight gain among pregnant women with obesity.
    Lancet. 2024 Mar 28:S0140-6736(24)00470-7. doi: 10.1016/S0140-6736(24)00470.
    >> Share

  39. LORUSSO D, Xiang Y, Hasegawa K, Scambia G, et al
    Pembrolizumab or placebo with chemoradiotherapy followed by pembrolizumab or placebo for newly diagnosed, high-risk, locally advanced cervical cancer (ENGOT-cx11/GOG-3047/KEYNOTE-A18): a randomised, double-blind, phase 3 clinical trial.
    Lancet. 2024 Mar 20:S0140-6736(24)00317-9. doi: 10.1016/S0140-6736(24)00317.
    >> Share

  40. TEWARI KS, Monk BJ
    Immunotherapy plus chemoradiotherapy in cervical cancer management.
    Lancet. 2024 Mar 20:S0140-6736(24)00468-9. doi: 10.1016/S0140-6736(24)00468.
    >> Share

  41. HEISLER M, Mitchell N, Arey W, Erenberg M, et al
    US abortion bans should not pre-empt the duty to provide life-saving abortion care to pregnant patients in medical emergencies.
    Lancet. 2024 Mar 19:S0140-6736(24)00551-8. doi: 10.1016/S0140-6736(24)00551.
    >> Share

  42. DADOUN S, Demmler-Harrison GJ, Ketwaroo P, Castro EC, et al
    Congenital toxoplasmosis of the brain caused by infection in late pregnancy.
    Lancet. 2024;403:1081-1082.
    >> Share

  43. MISHRA GD, Davies MC, Hillman S, Chung HF, et al
    Optimising health after early menopause.
    Lancet. 2024;403:958-968.
    >> Share

  44. HICKEY M, Basu P, Sassarini J, Stegmann ME, et al
    Managing menopause after cancer.
    Lancet. 2024;403:984-996.
    >> Share

  45. BROWN L, Hunter MS, Chen R, Crandall CJ, et al
    Promoting good mental health over the menopause transition.
    Lancet. 2024;403:969-983.
    >> Share

  46. HICKEY M, LaCroix AZ, Doust J, Mishra GD, et al
    An empowerment model for managing menopause.
    Lancet. 2024;403:947-957.
    >> Share

  47. HAWKES P, Scott J, Hickey M
    500 Strong: celebrating older women's bodies in menopause and beyond.
    Lancet. 2024;403:894-903.
    >> Share

  48. SAMARASEKERA U
    Martha Hickey: responding to the complexity of menopause.
    Lancet. 2024;403:893.
    >> Share

  49. THE LANCET
    Time for a balanced conversation about menopause.
    Lancet. 2024;403:877.
    >> Share

  50. NIELSEN OH, Gubatan JM, Kolho KL, Streett SE, et al
    Updates on the management of inflammatory bowel disease from periconception to pregnancy and lactation.
    Lancet. 2024 Mar 5:S0140-6736(24)00052-7. doi: 10.1016/S0140-6736(24)00052.
    >> Share

  51. ZAROCOSTAS J
    Renewed calls to scale-up cervical cancer screening.
    Lancet. 2024;403:797.
    >> Share

    February 2024
  52. PETERS RPH, Klausner JD, Mazzola L, Mdingi MM, et al
    Novel lateral flow assay for point-of-care detection of Neisseria gonorrhoeae infection in syndromic management settings: a cross-sectional performance evaluation.
    Lancet. 2024;403:657-664.
    >> Share

  53. THORNTON J
    Reducing patchiness in abortion care in the UK.
    Lancet. 2024 Feb 15:S0140-6736(24)00312-X. doi: 10.1016/S0140-6736(24)00312.
    >> Share

  54. HURRELL A, Webster L, Sparkes J, Battersby C, et al
    Repeat placental growth factor-based testing in women with suspected preterm pre-eclampsia (PARROT-2): a multicentre, parallel-group, superiority, randomised controlled trial.
    Lancet. 2024 Feb 8:S0140-6736(23)02357-7. doi: 10.1016/S0140-6736(23)02357.
    >> Share

  55. CERDEIRA AS, Karumanchi SA
    Serial placental growth factor-based testing in pre-eclampsia.
    Lancet. 2024 Feb 8:S0140-6736(23)02578-3. doi: 10.1016/S0140-6736(23)02578.
    >> Share

  56. LUCAS N, Rex S, Devroe S
    Treatment modalities for placenta accreta spectrum.
    Lancet. 2024;403:437.
    >> Share

  57. MORLEY LC, Sparey C, Wijeratne D, Turner K, et al
    Treatment modalities for placenta accreta spectrum - Authors' reply.
    Lancet. 2024;403:437-438.
    >> Share

    January 2024
  58. KAMYA MR, Kakuru A, Dorsey G
    Dihydroartemisinin-piperaquine for prevention of malaria in pregnant women living with HIV.
    Lancet. 2024 Jan 12:S0140-6736(24)00048-5. doi: 10.1016/S0140-6736(24)00048.
    >> Share

  59. BARSOSIO HC, Madanitsa M, Ondieki ED, Dodd J, et al
    Chemoprevention for malaria with monthly intermittent preventive treatment with dihydroartemisinin-piperaquine in pregnant women living with HIV on daily co-trimoxazole in Kenya and Malawi: a randomised, double-blind, placebo-controlled trial.
    Lancet. 2024 Jan 12:S0140-6736(23)02631-4. doi: 10.1016/S0140-6736(23)02631.
    >> Share

  60. RIAL-CRESTELO M, Lubusky M, Parra-Cordero M, Krofta L, et al
    Term planned delivery based on fetal growth assessment with or without the cerebroplacental ratio in low-risk pregnancies (RATIO37): an international, multicentre, open-label, randomised controlled trial.
    Lancet. 2024 Jan 11:S0140-6736(23)02228-6. doi: 10.1016/S0140-6736(23)02228.
    >> Share

  61. ELNAKIB S, Fair M, Mayrhofer E, Afifi M, et al
    Pregnant women in Gaza require urgent protection.
    Lancet. 2024 Jan 11:S0140-6736(23)02835-0. doi: 10.1016/S0140-6736(23)02835.
    >> Share

    December 2023
  62. CHAILLET N, Masse B, Grobman WA, Shorten A, et al
    Perinatal morbidity among women with a previous caesarean delivery (PRISMA trial): a cluster-randomised trial.
    Lancet. 2023 Dec 11:S0140-6736(23)01855-X. doi: 10.1016/S0140-6736(23)01855.
    >> Share

  63. OAKNIN A, Gladieff L, Martinez-Garcia J, Villacampa G, et al
    Atezolizumab plus bevacizumab and chemotherapy for metastatic, persistent, or recurrent cervical cancer (BEATcc): a randomised, open-label, phase 3 trial.
    Lancet. 2023 Dec 1:S0140-6736(23)02405-4. doi: 10.1016/S0140-6736(23)02405.
    >> Share

  64. MILESHKIN LR, Manoharan S
    Improving survival from metastatic, recurrent, or persistent cervical cancer.
    Lancet. 2023 Dec 1:S0140-6736(23)02690-9. doi: 10.1016/S0140-6736(23)02690.
    >> Share

    November 2023
  65. ADEPOJU P
    Nigeria targets almost 8 million girls with HPV vaccine.
    Lancet. 2023;402:1612.
    >> Share

  66. SINGH M, Wambua S, Lee SI, Okoth K, et al
    Autoimmune diseases and adverse pregnancy outcomes: an umbrella review.
    Lancet. 2023;402 Suppl 1:S84.
    >> Share

  67. HOBSON G, Dennis N
    Experiences of menopause in the Welsh NHS workplace: a focus group study.
    Lancet. 2023;402 Suppl 1:S51.
    >> Share

  68. JONG FC, Kotzur M, Amiri R, Ling J, et al
    Using a participatory approach to encourage uptake of breast, colorectal, and cervical cancer screening for Scottish Muslim women: a pilot qualitative study.
    Lancet. 2023;402 Suppl 1:S12.
    >> Share

  69. COWLING A, Nevens L, Contogiorgi N, Bradley N, et al
    Developing and piloting an intervention to reduce colposcopy non-attendance and corresponding inequalities: a mixed-methods study.
    Lancet. 2023;402 Suppl 1:S35.
    >> Share

    October 2023
  70. KOTANI T, Tano S
    Long-term effects of gestational weight gain on mortality.
    Lancet. 2023 Oct 19:S0140-6736(23)01837-8. doi: 10.1016/S0140-6736(23)01837.
    >> Share

  71. HINKLE SN, Mumford SL, Grantz KL, Mendola P, et al
    Gestational weight change in a diverse pregnancy cohort and mortality over 50 years: a prospective observational cohort study.
    Lancet. 2023 Oct 19:S0140-6736(23)01517-9. doi: 10.1016/S0140-6736(23)01517.
    >> Share

  72. BHAN N, McDougal L
    Centring agency and norms to meet the health needs of pregnant adolescents.
    Lancet. 2023 Oct 11:S0140-6736(23)02226-2. doi: 10.1016/S0140-6736(23)02226.
    >> Share

  73. SABET F, Prost A, Rahmanian S, Al Qudah H, et al
    The forgotten girls: the state of evidence for health interventions for pregnant adolescents and their newborns in low-income and middle-income countries.
    Lancet. 2023 Oct 11:S0140-6736(23)01682-3. doi: 10.1016/S0140-6736(23)01682.
    >> Share

    August 2023
  74. YAQUB S, Bjork I, Sugulle M, Folseraas T, et al
    Biopsy helpful in diagnosing a liver mass in pregnancy: focal nodular hyperplasia.
    Lancet. 2023;402:e10.
    >> Share

  75. JAFFE S
    Abortion foes threaten PEPFAR.
    Lancet. 2023;402:598.
    >> Share

  76. CAHILL EP
    Adding a COX-2 inhibitor improves efficacy of emergency contraception.
    Lancet. 2023 Aug 16:S0140-6736(23)01612-4. doi: 10.1016/S0140-6736(23)01612.
    >> Share

  77. LI RHW, Lo SST, Gemzell-Danielsson K, Fong CHY, et al
    Oral emergency contraception with levonorgestrel plus piroxicam: a randomised double-blind placebo-controlled trial.
    Lancet. 2023 Aug 16:S0140-6736(23)01240-0. doi: 10.1016/S0140-6736(23)01240.
    >> Share

    July 2023
  78. DASGUPTA N, Ajazi EM, Schwartz TA, Marshall SW, et al
    Misclassification of overdose events in the X:BOT study.
    Lancet. 2023 Jul 19:S0140-6736(23)00113-7. doi: 10.1016/S0140-6736(23)00113.
    >> Share

  79. SABBAH N, Demar M, Sogbo F, Zappa M, et al
    Recurrent vomiting and confusion in pregnancy: hypercalcaemia due to parathyroid adenoma.
    Lancet. 2023;402:62-63.
    >> Share

  80. STRANDELL A, Hellgren M
    Time to stop routine prescription of low-molecular-weight heparin to women with recurrent pregnancy loss and inherited thrombophilia.
    Lancet. 2023;402:6-7.
    >> Share

    June 2023
  81. CLUVER CA, Walker SP
    Early delivery for pre-eclampsia might save lives in low-income and middle-income settings.
    Lancet. 2023 Jun 29:S0140-6736(23)00824-3. doi: 10.1016/S0140-6736(23)00824.
    >> Share

  82. BEARDMORE-GRAY A, Vousden N, Seed PT, Vwalika B, et al
    Planned delivery or expectant management for late preterm pre-eclampsia in low-income and middle-income countries (CRADLE-4): a multicentre, open-label, randomised controlled trial.
    Lancet. 2023 Jun 29:S0140-6736(23)00688-8. doi: 10.1016/S0140-6736(23)00688.
    >> Share

  83. LUCAS DN, Bamber JH, Quasim S
    Perinatal outcomes and the role of obstetric anaesthesia interventions.
    Lancet. 2023;401:2038-2039.
    >> Share

  84. QUENBY S, Booth K, Hiller L, Coomarasamy A, et al
    Heparin for women with recurrent miscarriage and inherited thrombophilia (ALIFE2): an international open-label, randomised controlled trial.
    Lancet. 2023 Jun 1:S0140-6736(23)00693-1. doi: 10.1016/S0140-6736(23)00693.
    >> Share

    May 2023
  85. SHAHEEN-HUSSAIN S, Lombard A, Basile S
    Confronting medical colonialism and obstetric violence in Canada.
    Lancet. 2023;401:1763-1765.
    >> Share

  86. MCCURRY J
    Japan approves abortion pill.
    Lancet. 2023;401:1558.
    >> Share

  87. MOHIDDIN A, Semrau KEA, Simon J, Langlois EV, et al
    The ethical, economic, and developmental imperative to prevent small vulnerable newborns and stillbirths: essential actions to improve the country and global response.
    Lancet. 2023 May 5:S0140-6736(23)00721-3. doi: 10.1016/S0140-6736(23)00721.
    >> Share

    April 2023
  88. HEISLER M, Cox-Toure T, Kaufman R
    US abortion bans violate patients' right to information and to health.
    Lancet. 2023 Apr 24:S0140-6736(23)00808-5. doi: 10.1016/S0140-6736(23)00808.
    >> Share

  89. JAFFE S
    Drug developers caution against US mifepristone ban.
    Lancet. 2023;401:1325-1326.
    >> Share

  90. SHAND AW, Kidson-Gerber GL
    Anaemia in pregnancy: a major global health problem.
    Lancet. 2023 Apr 20:S0140-6736(23)00396-3. doi: 10.1016/S0140-6736(23)00396.
    >> Share

  91. PASRICHA SR, Mwangi MN, Moya E, Ataide R, et al
    Ferric carboxymaltose versus standard-of-care oral iron to treat second-trimester anaemia in Malawian pregnant women: a randomised controlled trial.
    Lancet. 2023 Apr 20:S0140-6736(23)00278-7. doi: 10.1016/S0140-6736(23)00278.
    >> Share

  92. CHANDYO RK, Kvestad I, Ulak M, Ranjitkar S, et al
    The effect of vitamin B12 supplementation during pregnancy on infant growth and development in Nepal: a community-based, double-blind, randomised, placebo-controlled trial.
    Lancet. 2023 Apr 6:S0140-6736(23)00346-X. doi: 10.1016/S0140-6736(23)00346.
    >> Share

    March 2023
  93. BERGH C, Lundin K
    No benefit to pregnancy or livebirth by time-lapse-based embryo selection in IVF.
    Lancet. 2023 Mar 30:S0140-6736(23)00219-2. doi: 10.1016/S0140-6736(23)00219.
    >> Share

  94. LEDERMAN S, Ottery FD, Cano A, Santoro N, et al
    Fezolinetant for treatment of moderate-to-severe vasomotor symptoms associated with menopause (SKYLIGHT 1): a phase 3 randomised controlled study.
    Lancet. 2023 Mar 13:S0140-6736(23)00085-5. doi: 10.1016/S0140-6736(23)00085.
    >> Share

  95. PRAGUE JK
    Neurokinin 3 receptor antagonists for menopausal vasomotor symptoms.
    Lancet. 2023 Mar 13:S0140-6736(23)00353-7. doi: 10.1016/S0140-6736(23)00353.
    >> Share

  96. MORLEY LC, Sparey C, Wijeratne D, Turner K, et al
    A planned caesarean hysterectomy for placenta accreta spectrum at 35 weeks of gestation: antenatal identification and a multidisciplinary approach to manage an increasing condition.
    Lancet. 2023;401:856-857.
    >> Share

  97. CLUVER C, de Groot C, Mol BW, Murphy KE, et al
    The need for appropriate language in the debate on medicalisation of pregnancy.
    Lancet. 2023;401:818-819.
    >> Share

  98. KAKURU A, Jagannathan P
    Can we reduce malaria in pregnancy and improve birth outcomes?
    Lancet. 2023 Mar 10:S0140-6736(23)00101-0. doi: 10.1016/S0140-6736(23)00101.
    >> Share

  99. MADANITSA M, Barsosio HC, Minja DTR, Mtove G, et al
    Effect of monthly intermittent preventive treatment with dihydroartemisinin-piperaquine with and without azithromycin versus monthly sulfadoxine-pyrimethamine on adverse pregnancy outcomes in Africa: a double-blind randomised, partly placebo-controlle
    Lancet. 2023 Mar 10:S0140-6736(22)02535-1. doi: 10.1016/S0140-6736(22)02535.
    >> Share

  100. HAWKES S, Kedia S, Odunga S, Dahal M, et al
    From flowers to menstrual-flow trackers: the corporatisation of women's equality and wellbeing.
    Lancet. 2023 Mar 7:S0140-6736(23)00456-7. doi: 10.1016/S0140-6736(23)00456.
    >> Share

    February 2023
  101. MURRAY CJL
    A systematic analysis points in the wrong direction for cervical cancer elimination - Author's reply.
    Lancet. 2023;401:555-556.
    >> Share

  102. JACKSON A
    A systematic analysis points in the wrong direction for cervical cancer elimination.
    Lancet. 2023;401:555.
    >> Share

  103. DUGOFF L
    The use of cell-free DNA technology in pregnancy loss.
    Lancet. 2023 Feb 1:S0140-6736(23)00182-4. doi: 10.1016/S0140-6736(23)00182.
    >> Share

  104. SCHLAIKJAER HARTWIG T, Ambye L, Gruhn JR, Petersen JF, et al
    Cell-free fetal DNA for genetic evaluation in Copenhagen Pregnancy Loss Study (COPL): a prospective cohort study.
    Lancet. 2023 Feb 1:S0140-6736(22)02610-1. doi: 10.1016/S0140-6736(22)02610.
    >> Share

  105. HORNE AW, Tong S, Moakes CA, Middleton LJ, et al
    Combination of gefitinib and methotrexate to treat tubal ectopic pregnancy (GEM3): a multicentre, randomised, double-blind, placebo-controlled trial.
    Lancet. 2023 Feb 1:S0140-6736(22)02478-3. doi: 10.1016/S0140-6736(22)02478.
    >> Share

  106. SONALKAR S, Gilmore E
    A fresh look at treatment for ectopic pregnancy.
    Lancet. 2023 Feb 1:S0140-6736(23)00181-2. doi: 10.1016/S0140-6736(23)00181.
    >> Share

    January 2023
  107. ELLINGTON S, Jatlaoui TC
    COVID-19 vaccination is effective at preventing severe illness and complications during pregnancy.
    Lancet. 2023 Jan 17:S0140-6736(22)02613-7. doi: 10.1016/S0140-6736(22)02613.
    >> Share

  108. VILLAR J, Soto Conti CP, Gunier RB, Ariff S, et al
    Pregnancy outcomes and vaccine effectiveness during the period of omicron as the variant of concern, INTERCOVID-2022: a multinational, observational study.
    Lancet. 2023 Jan 17:S0140-6736(22)02467-9. doi: 10.1016/S0140-6736(22)02467.
    >> Share

    December 2022
  109. SHEIKH J, Allotey J, Kew T, Fernandez-Felix BM, et al
    Effects of race and ethnicity on perinatal outcomes in high-income and upper-middle-income countries: an individual participant data meta-analysis of 2 198 655 pregnancies.
    Lancet. 2022;400:2049-2062.
    >> Share

    November 2022
  110. SAITO M, McGready R, Tinto H, Rouamba T, et al
    Pregnancy outcomes after first-trimester treatment with artemisinin derivatives versus non-artemisinin antimalarials: a systematic review and individual patient data meta-analysis.
    Lancet. 2022 Nov 25:S0140-6736(22)01881-5. doi: 10.1016/S0140-6736(22)01881.
    >> Share

  111. SLUTSKER L, Leke RGF
    First-trimester use of ACTs for malaria treatment in pregnancy.
    Lancet. 2022 Nov 25:S0140-6736(22)02166-3. doi: 10.1016/S0140-6736(22)02166.
    >> Share

  112. OLAJIDE N, Robb K, Niedzwiedz C, Jani B, et al
    Cervical cancer risk factors in eight west African countries: cross-sectional analysis of the demographic and health survey 2017-20.
    Lancet. 2022;400 Suppl 1:S68.
    >> Share

  113. ANDREAE G, Scott S, Nguyen G, Bell Z, et al
    Food insecurity among pregnant women living in high-income countries: a systematic review.
    Lancet. 2022;400 Suppl 1:S17.
    >> Share

    October 2022
  114. DASHRAATH P, Thong WSE, Ang M, Lee YM, et al
    Interferon shrinks spleen in pregnant patient with myeloproliferative neoplasm.
    Lancet. 2022;400:e11.
    >> Share

  115. BAUD D, Nielsen-Saines K, Mattar C, Musso D, et al
    Monkeypox exposure during pregnancy: what does UK public health guidance advise? - Authors' reply.
    Lancet. 2022;400:1509-1510.
    >> Share

  116. ADLER H, Taggart R
    Monkeypox exposure during pregnancy: what does UK public health guidance advise?
    Lancet. 2022;400:1509.
    >> Share

  117. VAN LENNEP JER, Nerenberg KA
    Delivering evidence to prevent recurrent venous thromboembolism in pregnancy.
    Lancet. 2022 Oct 28. pii: S0140-6736(22)02030.
    >> Share

  118. BISTERVELS IM, Buchmuller A, Wiegers HMG, Ni Ainle F, et al
    Intermediate-dose versus low-dose low-molecular-weight heparin in pregnant and post-partum women with a history of venous thromboembolism (Highlow study): an open-label, multicentre, randomised, controlled trial.
    Lancet. 2022 Oct 28. pii: S0140-6736(22)02128.
    >> Share

  119. HODGETTS MORTON V, Toozs-Hobson P, Moakes CA, Middleton L, et al
    Monofilament suture versus braided suture thread to improve pregnancy outcomes after vaginal cervical cerclage (C-STICH): a pragmatic randomised, controlled, phase 3, superiority trial.
    Lancet. 2022;400:1426-1436.
    >> Share

  120. GLYDE T
    LGBTQIA+ menopause: room for improvement.
    Lancet. 2022 Oct 18. pii: S0140-6736(22)01935.
    >> Share

  121. KHALIL A, Samara A, Ladhani S, O'Brien P, et al
    Monkeypox and pregnancy: time for global surveillance and prevention strategies.
    Lancet. 2022;400:1193.
    >> Share

    September 2022
  122. DONNEZ J, Taylor HS, Stewart EA, Bradley L, et al
    Linzagolix with and without hormonal add-back therapy for the treatment of symptomatic uterine fibroids: two randomised, placebo-controlled, phase 3 trials.
    Lancet. 2022;400:896-907.
    >> Share

  123. DE LANGE ME, Huirne JAF
    Linzagolix: an oral gonadotropin-releasing hormone receptor antagonist treatment for uterine fibroid-associated heavy menstrual bleeding.
    Lancet. 2022;400:866-867.
    >> Share

    August 2022
  124. ENDLER M, Petro G, Gemzell Danielsson K, Grossman D, et al
    A telemedicine model for abortion in South Africa: a randomised, controlled, non-inferiority trial.
    Lancet. 2022;400:670-679.
    >> Share

  125. WINIKOFF B, Lohr PA
    Randomised trials of medical abortion provide some but not all the answers.
    Lancet. 2022;400:638-639.
    >> Share

  126. ROBERTS SL, Kendall GS, Edwards S, Pandya P, et al
    Screening policies for cytomegalovirus in pregnancy in the era of antivirals.
    Lancet. 2022;400:489-490.
    >> Share

    July 2022
  127. HAAKENSTAD A, Angelino O, Irvine CMS, Bhutta ZA, et al
    Measuring contraceptive method mix, prevalence, and demand satisfied by age and marital status in 204 countries and territories, 1970-2019: a systematic analysis for the Global Burden of Disease Study 2019.
    Lancet. 2022;400:295-327.
    >> Share

  128. PRADHAN MR
    Contraceptive mix and informed choice.
    Lancet. 2022;400:255-257.
    >> Share

  129. JAFFE S
    "Chaos" for patients and providers after US abortion ruling.
    Lancet. 2022;400:85-86.
    >> Share

  130. HIAM L, Mateescu I, Spiegel P
    Improving access to contraception and abortion in Romania in the context of the conflict in Ukraine.
    Lancet. 2022 Jul 8. pii: S0140-6736(22)01275.
    >> Share

  131. JAFFE S
    Federal abortion rights end, but not legal challenges.
    Lancet. 2022;400:13-14.
    >> Share

    June 2022
  132. DASHRAATH P, Nielsen-Saines K, Mattar C, Musso D, et al
    Guidelines for pregnant individuals with monkeypox virus exposure.
    Lancet. 2022 Jun 21. pii: S0140-6736(22)01063.
    >> Share

  133. GIUDICE LC, As-Sanie S, Arjona Ferreira JC, Becker CM, et al
    Once daily oral relugolix combination therapy versus placebo in patients with endometriosis-associated pain: two replicate phase 3, randomised, double-blind, studies (SPIRIT 1 and 2).
    Lancet. 2022;399:2267-2279.
    >> Share

  134. SARASWAT L, Bhattacharya S
    Relugolix combination therapy for endometriosis pain.
    Lancet. 2022;399:2244-2245.
    >> Share

  135. HOLT E
    Poland to introduce controversial pregnancy register.
    Lancet. 2022;399:2256.
    >> Share

  136. THE LANCET
    Attitudes towards menopause: time for change.
    Lancet. 2022;399:2243.
    >> Share

  137. O'BRIEN E, Rich M
    Obstetric violence in historical perspective.
    Lancet. 2022;399:2183-2185.
    >> Share

  138. REED SD, Zhou X, Ichikawa L, Gatz JL, et al
    Intrauterine device-related uterine perforation incidence and risk (APEX-IUD): a large multisite cohort study.
    Lancet. 2022;399:2103-2112.
    >> Share

  139. BARTZ D
    Incidence of perforation with intrauterine devices.
    Lancet. 2022;399:2076-2077.
    >> Share

    May 2022
  140. SCHAEDEL Z, Rymer J
    Menopause care and over the counter vaginal oestradiol.
    Lancet. 2022 May 31. pii: S0140-6736(22)00952.
    >> Share

  141. JARDINE J, Harris T, Khalil A, van der Meulen J, et al
    Adverse pregnancy outcomes: biological essentialism versus embodied biology - Authors' reply.
    Lancet. 2022;399:2014.
    >> Share

  142. RAVI K, Janiak E
    Adverse pregnancy outcomes: biological essentialism versus embodied biology.
    Lancet. 2022;399:2013-2014.
    >> Share

  143. SASIENI P, Castanon A
    HPV vaccination and cervical cancer screening - Authors' reply.
    Lancet. 2022;399:1940.
    >> Share

  144. BEWLEY S
    HPV vaccination and cervical cancer screening.
    Lancet. 2022;399:1939.
    >> Share

  145. KAMAMOTO S, Murayama A, Hamaki T, Kusumi E, et al
    HPV vaccination and cervical cancer screening.
    Lancet. 2022;399:1939-1940.
    >> Share

  146. JAFFE S
    Health organizations fear effects of US abortion ruling.
    Lancet. 2022;399:1854.
    >> Share

  147. VOSS FO, van Beurden M, Jordanova ES
    Topical imiquimod as first-line treatment for vulvar intraepithelial neoplasia.
    Lancet. 2022;399:1755-1757.
    >> Share

  148. TRUTNOVSKY G, Reich O, Joura EA, Holter M, et al
    Topical imiquimod versus surgery for vulvar intraepithelial neoplasia: a multicentre, randomised, phase 3, non-inferiority trial.
    Lancet. 2022;399:1790-1798.
    >> Share

  149. DASHRAATH P, Chen K, Htet ZW, Chan SY, et al
    Pre-eclampsia with paradoxical polyuria: diabetes insipidus in pregnancy.
    Lancet. 2022;399:1809.
    >> Share

    April 2022
  150. MAKONI M
    Hope for access to abortion in Kenya.
    Lancet. 2022;399:1456.
    >> Share

  151. CROSBIE EJ, Kitson SJ, McAlpine JN, Mukhopadhyay A, et al
    Endometrial cancer.
    Lancet. 2022;399:1412-1428.
    >> Share

    March 2022
  152. BOOTH A
    Activists welcome Colombia's decriminalisation of abortion.
    Lancet. 2022;399:899.
    >> Share

  153. MANCA T, Baylis F, Munoz FM, Top KA, et al
    Prioritise research on vaccines for pregnant and breastfeeding women.
    Lancet. 2022;399:890-893.
    >> Share

    February 2022
  154. PASHANKAR R, Prabulos AM, Feder HM Jr
    A woman pregnant with twins has fever, haemolysis, and thrombocytopenia caused by babesiosis: could be confused with HELLP syndrome.
    Lancet. 2022;399:e10.
    >> Share

  155. KALAFAT E, Magee LA, von Dadelszen P, Heath P, et al
    COVID-19 booster doses in pregnancy and global vaccine equity.
    Lancet. 2022 Feb 18. pii: S0140-6736(22)00166.
    >> Share

  156. GERSHENSON DM, Miller A, Brady WE, Paul J, et al
    Trametinib versus standard of care in patients with recurrent low-grade serous ovarian cancer (GOG 281/LOGS): an international, randomised, open-label, multicentre, phase 2/3 trial.
    Lancet. 2022;399:541-553.
    >> Share

  157. BLAGDEN SP
    Targeting MAPK in recurrent, low-grade serous ovarian cancer.
    Lancet. 2022;399:499-501.
    >> Share

  158. CERDEIRA AS, Ismail L, Moore N, George B, et al
    Retroperitoneal leiomyomatosis: a benign outcome of power morcellation with potentially serious consequences.
    Lancet. 2022;399:554.
    >> Share

    January 2022
  159. HUG L, You D, Blencowe H, Moran AC, et al
    Strengthening the reporting of stillbirths globally - Authors' reply.
    Lancet. 2022;399:142.
    >> Share

  160. DAS AM, Janardhanan R
    Strengthening the reporting of stillbirths globally.
    Lancet. 2022;399:141.
    >> Share

  161. JOOS O, Swiney C, Sferrazza L
    Strengthening the reporting of stillbirths globally.
    Lancet. 2022;399:140-141.
    >> Share

    December 2021
  162. JAFFE S
    US Supreme Court expected to weaken abortion rights.
    Lancet. 2021;398:2137-2138.
    >> Share

    November 2021
  163. SANSON C, Majer M, Pautier P, Gouy S, et al
    Unexplained uterine atrophy following neoadjuvant chemotherapy in fertility sparing management of cervical cancer.
    Lancet. 2021;398:e17.
    >> Share

  164. FALCARO M, Castanon A, Ndlela B, Checchi M, et al
    The effects of the national HPV vaccination programme in England, UK, on cervical cancer and grade 3 cervical intraepithelial neoplasia incidence: a register-based observational study.
    Lancet. 2021 Nov 3. pii: S0140-6736(21)02178.
    >> Share

  165. CRUICKSHANK ME, Grigore M
    Cervical cancers avoided by HPV immunisation.
    Lancet. 2021 Nov 3. pii: S0140-6736(21)02396.
    >> Share

  166. JARDINE J, Walker K, Gurol-Urganci I, Webster K, et al
    Adverse pregnancy outcomes attributable to socioeconomic and ethnic inequalities in England: a national cohort study.
    Lancet. 2021 Nov 1. pii: S0140-6736(21)01595.
    >> Share

    October 2021
  167. THE LANCET
    Abortion bans in the USA harm health equity.
    Lancet. 2021;398:1461.
    >> Share


Free Medical Abstracts
Privacy Policy
Sponsors
Share

© Amedeo 1997-2016